Ren and Pharmaceuticals raised more than 834 million yuan to invest in industrial marijuana projects, but the cooperative environmental assessment agency is now "black history"

Raised 834 million yuan main investment in industrial cannabis project "problems" cooperative EIA institutions constantly according to the plan announcement shows that Renhe Pharmaceuticals intends to issue a maximum number of shares of 372 million shares, the total amount of funds to be raised is not more than 834 million yuan, respectively, for investment in "Renhe Xianghe Industrial Marijuana Integrated Utilization Industry Project," "Chinese medicine classic industry upgrade technology reform project," "Ren and smart pharmaceutical logistics park project," "Ben and research and development center construction projects."
, "Renhe Xianghe Industrial Marijuana Comprehensive Utilization Industry Project" is intended to raise 279 million yuan, the project construction period of 3 years, the main implementation of the project for Renhe Pharmaceutical Holdings subsidiary Renhe Xianghe.
the project is divided into three phases of construction, the construction includes extraction workshop, constant temperature and humidity storage, processing workshop, integrated building, power center, sewage treatment station and supporting plant projects.
phase III project will achieve an annual production capacity of 50 tons of industrial cannabis extract cannabidiol (CBD content of 99%).
for this layout of industrial cannabis products, Ren and Pharmaceuticals said that there are currently fewer suppliers of cannabidiol (CBD) raw materials of a certain size in the world, and the huge downstream market application of industrial cannabis extracts is becoming increasingly important.
therefore, it intends to become an influential supplier of cannabidiol (CBD) raw materials through the launch of this industrial cannabis integrated use industry project, providing a new growth point for its development.
According to the "Second Information Disclosure of Environmental Impact Assessment of Qiqiharren and Xianghe Industrial Marijuana Industry Project" published on the official website of Renhe Pharmaceuticals, the environmental impact statement of Renhehe Industrial Marijuana Integrated Utilization Industry Project was prepared by Heilongjiang Auspicious Tian Environmental Engineering Consulting Co., Ltd. (hereinafter referred to as "Auspicious Tianhuan").
it is worth noting that there is a lot of "black history" in the EIA units that Ren and the pharmaceutical industry cooperate with.
According to the "Notice on the Technical Review of Environmental Impact Assessment Documents in Heilongjiang Province for 2017 and The Notice of Handling Opinions" issued by Heilongjiang Eco-Bad Environment Department on August 29, 2018, auspicious Tianhuan has prepared an environmental impact report form for construction projects with an annual output of 700 tons of PE winding film and 120,000 paper barrels. , there are "location is located in Hailin City Economic and Technological Development Zone, and planning, planning EIA and review of the compliance analysis is insufficient;
May 4, 2018, in the Fujian Provincial Environmental Protection Department in the third and fourth quarter of 2016 EIA assessment, auspicious Tianhuan due to the failure to submit spot check assessment materials, its assessment results were directly assessed as unqualified, and the Fujian Provincial Environmental Ecology Department requested a deadline of 6 months for rectification.
October 12, 2018, the Fujian Ecological Environment Bureau conducted a credit assessment in 2016 and 2017 by the EIA institutions and their EIA personnel conducting business, of which Auspicious Tianhuan's credit rating was rated as "generally disrepassionable" and ordered to be corrected for a period of three months.
the "problems" of the Co-operation EIA Agency continue, is ren and pharmaceutical industry's EIA report trustworthy? Because of drug quality problems, subsidiaries are frequently fined Ren and Pharmaceutical's holding subsidiaries are frequently punished for drug quality problems, of which the "black list" of the largest number of times is Jiangxi Pharmaceutical Co., Ltd. (hereinafter referred to as "Jiangxi Pharmaceuticals"), Tianying information shows that Ren and Pharmaceutical's shareholding in its shareholding is 54.91 percent.
2016 to 2019, Jiangxi Pharmaceuticals was punished 10 times for drug quality problems, according to global health statistics.
December 3, 2019, Jiangxi Pharmaceuticals was fined 1281 million yuan and fined 512,500 yuan by the Jiangxi Provincial Drug Administration for producing and selling "Kramycin Dispersion Tablets".
2018, Jiangxi pharmaceutical drug quality problems have also been on the "black list" many times.
Global Health Statistics, In 2018, Jiangxi Pharmaceuticals was punished up to four times for drug quality problems, namely: On July 30, 2018, Jiangxi Pharmaceuticals was punished by the Jiangxi Food and Drug Administration for "producing and selling sodium nucleobin phosphate injections."
On July 24, 2018, Jiangxi Pharmaceuticals was fined 147,000 yuan and fined 293,000 yuan by the Nanchang Food and Drug Administration for "non-compliance with the regulations for the production of small nomycin injections of sulfuric acid."
On April 20, 2018, Jiangxi Pharmaceuticals was confiscated and doubled by the Nanchang Food and Drug Administration for "producing iron sulfate tablets that do not conform to the regulations" and fined a total of 382,000 yuan. On the same day in
, Jiangxi Pharmaceutical was confiscated by the Jiangxi Food and Drug Administration of 175,000 yuan and fined twice as much as 35,000 yuan for "producing and selling injections of small nomycin sulfate based on inferior drugs".
2016 to 2017, Jiangxi Pharmaceuticals was also punished five times for drug quality problems.
in addition, two other subsidiaries of Ren and Pharmaceuticals, Jiangxi Copper Guren and Pharmaceutical Co., Ltd. (hereinafter referred to as "Copper Guren and"), Jiangxi Jiang Pharmaceutical Co., Ltd. ("Jiang Pharmaceutical") have also been fined heavily for the quality of the drugs.
According to (Yi City) Municipal Supervision (Drug) Penalty (2019) No. 1 document, copper drum ren and because of "the production of healthy children's clearing solution (identification) item (1) chemical reaction does not show a positive reaction does not meet the provisions", Yichun City Market Supervision Bureau confiscated the illegal income of 3817 million yuan and twice the fine, a total fine of 1.1452 million yuan.
October 16, 2019, Jiang Pharmaceuticals was confiscated by the Jiangxi Provincial Drug Administration for "not conforming to the requirements for the dispersion and uniformity of the dispersion of kramycin dispersion tablets sold."
day eye inspection information shows that Ren and Pharmaceuticals 100% of the control of Copper Guren and, while Jiang Pharmaceutical Holdings 54.91 percent.
subsidiaries are frequently fined for drug quality problems, and the quality of Ren and pharmaceutical products or hidden worries.
.